Strategic Acquisition Impact Henry Schein's majority acquisition of Acentus assets signals a shift in distribution channels and potential access to broader customer bases in dental and medical supply networks. This creates opportunities to position CGM solutions within larger enterprise sales motions and leverage Schein’s B2B relationships for increased medtech adoption.

New Channel Access With assets now under Henry Schein, explore joint go-to-market strategies, co-marketing, and bundled offerings that align CGMs with Henry Schein’s existing care delivery ecosystems to reach clinics, pharmacies, and home health providers.

Home CGM Demand Acentus specializes in delivering continuous glucose monitors to homes and simplifying Medicare qualification, indicating strong demand for home-based diabetes management solutions that can be presented to health plans and patient care teams seeking cost-effective chronic disease management.

Tech-Driven Referrals The ANSWERS referral portal and real-time clinician insights highlight an opportunity to upsell data integration, patient monitoring software, and telehealth workflows to clinics and hospital systems seeking seamless CGM referral and patient onboarding.

Scale and Partnerships Revenue is substantial and the company emphasizes patient and clinician satisfaction. This positions Acentus as a viable partner for large health systems, durable medical equipment providers, and capitated care programs aiming to expand CGM access and improve outcomes through scalable delivery.